The Latin America, Middle East and Africa Conjunctivitis Treatment Market would witness market growth of 7.1% CAGR during the forecast period (2023-2030).
The conjunctivitis treatment market refers to the sector within the healthcare industry dedicated to addressing and providing therapeutic interventions for conjunctivitis, commonly known as pink eye. This market encompasses various pharmaceuticals, medical devices, and treatment modalities designed to alleviate symptoms and manage conjunctivitis, including those caused by viral, bacterial, allergic, or irritant factors. The market stakeholders include pharmaceutical companies, healthcare providers, ophthalmologists, and researchers. The market is characterized by ongoing research and development efforts to enhance treatment efficacy, minimize side effects, and introduce innovative solutions, contributing to improving patient outcomes.
In recent years, the conjunctivitis treatment market has witnessed significant advancements driven by rigorous research and development activities. Pharmaceutical innovations, coupled with a deeper understanding of the underlying causes of conjunctivitis, have introduced targeted treatment modalities. These innovations encompass a range of pharmaceutical options, including antibiotics for bacterial conjunctivitis, antivirals for viral forms, and anti-allergic medications for allergic conjunctivitis. Additionally, the market has seen the emergence of medical devices and eye drops designed to provide relief and facilitate a more rapid recovery.
According to the Ministry of Economy of UAE, healthcare expenditures in the UAE are expected to rise to $21.3 billion by 2021, which is projected to account for 4.6% of the country's GDP by 2026. A decade survey to estimate future spending indicates that healthcare spending will reach $26 billion by 2028. The UAE market boasts an average of $1,200 in healthcare spending per capita, placing the country in the top 20. Furthermore, medical tourism in the UAE is expected to grow to AED 14 billion by the end of 2021, and it could touch AED 19 billion by 2023. Therefore, the rising medical tourism and expansion of the region's healthcare sector are propelling the market's growth.
The Brazil market dominated the LAMEA Conjunctivitis Treatment Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $128.9 Million by 2030. The Argentina market is registering a CAGR of 7.6% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 6.7% during (2023 - 2030).
Based on Disease Type, the market is segmented into Allergic Conjunctivitis, Viral Conjunctivitis, and Bacterial Conjunctivitis. Based on Drug Class, the market is segmented into Anti-allergic, Antiviral, Artificial Tears, and Antibiotics. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The conjunctivitis treatment market refers to the sector within the healthcare industry dedicated to addressing and providing therapeutic interventions for conjunctivitis, commonly known as pink eye. This market encompasses various pharmaceuticals, medical devices, and treatment modalities designed to alleviate symptoms and manage conjunctivitis, including those caused by viral, bacterial, allergic, or irritant factors. The market stakeholders include pharmaceutical companies, healthcare providers, ophthalmologists, and researchers. The market is characterized by ongoing research and development efforts to enhance treatment efficacy, minimize side effects, and introduce innovative solutions, contributing to improving patient outcomes.
In recent years, the conjunctivitis treatment market has witnessed significant advancements driven by rigorous research and development activities. Pharmaceutical innovations, coupled with a deeper understanding of the underlying causes of conjunctivitis, have introduced targeted treatment modalities. These innovations encompass a range of pharmaceutical options, including antibiotics for bacterial conjunctivitis, antivirals for viral forms, and anti-allergic medications for allergic conjunctivitis. Additionally, the market has seen the emergence of medical devices and eye drops designed to provide relief and facilitate a more rapid recovery.
According to the Ministry of Economy of UAE, healthcare expenditures in the UAE are expected to rise to $21.3 billion by 2021, which is projected to account for 4.6% of the country's GDP by 2026. A decade survey to estimate future spending indicates that healthcare spending will reach $26 billion by 2028. The UAE market boasts an average of $1,200 in healthcare spending per capita, placing the country in the top 20. Furthermore, medical tourism in the UAE is expected to grow to AED 14 billion by the end of 2021, and it could touch AED 19 billion by 2023. Therefore, the rising medical tourism and expansion of the region's healthcare sector are propelling the market's growth.
The Brazil market dominated the LAMEA Conjunctivitis Treatment Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $128.9 Million by 2030. The Argentina market is registering a CAGR of 7.6% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 6.7% during (2023 - 2030).
Based on Disease Type, the market is segmented into Allergic Conjunctivitis, Viral Conjunctivitis, and Bacterial Conjunctivitis. Based on Drug Class, the market is segmented into Anti-allergic, Antiviral, Artificial Tears, and Antibiotics. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Novartis AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- F.Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- AbbVie, Inc.
- AFT Pharmaceuticals
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
Market Report Segmentation
By Disease Type- Allergic Conjunctivitis
- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Anti-allergic
- Antiviral
- Artificial Tears
- Antibiotics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Conjunctivitis Treatment Market, by Disease Type
Chapter 5. LAMEA Conjunctivitis Treatment Market, by Drug Class
Chapter 6. LAMEA Conjunctivitis Treatment Market, by Distribution Channel
Chapter 7. LAMEA Conjunctivitis Treatment Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- Novartis AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- AbbVie, Inc.
- AFT Pharmaceuticals
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
